The fact that women’s health has long been underprioritized is common knowledge. Organon, with roots going back to 1923 and having sharpened its focus on women’s health post its 2021 spinoff from Merck & Co., aims to address significant gaps in treatment and care. “Our commitment to women’s health is not just a part of our corporate strategy; it’s at the core of who we are as a company,” said Dr. Juan Camilo Arjona Ferreira, chief medical officer at the company, in a recent interview.
Organon sees women’s health as encompassing more than just reproductive issues. “It’s a continuum that spans a woman’s entire life,” said Arjona, a gynecologist by training. “There’s plenty of opportunities across the board because women’s health has been understudied and underappreciated.”Organon’s approach to women’s health challenges